Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects

European Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2011, Pages 39-45

  Bae, Jung Woo ^a   Choi, Chang Ik ^a   Lee, Jin Hee ^a   Jang, Choon Gon ^a   Chung, Myeon Woo ^b   Lee, Seok Yong ^a  

^a Sungkyunkwan University   (South Korea)

^b Korea Drug and Food Administration   (South Korea)

Author keywords

Ezetimibe; Glucuronidation; Polymorphism; UGT1A1

Indexed keywords

EZETIMIBE; GLUCURONOSYLTRANSFERASE 1A1;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; UGT1A1 GENE; WILD TYPE;

ALLELES; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; AZETIDINES; FEMALE; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; MALE; POLYMORPHISM, GENETIC;

EID: 79251593578     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0899-x     Document Type: Article

References (27)

1. JE Patrick T Kosoglou KL Stauber KB Alton SE Maxwell Y Zhu P Statkevich R Iannucci S Chowdhury M Affrime MN Cayen 2002 Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects Drug Metab Dispos 30 430 437 1:CAS:528:DC%2BD38Xis1OlsLg%3D 10.1124/dmd.30.4.430 11901097
2. T Kosoglou P Statkevich AO Johnson-Levonas JF Paolini AJ Bergman KB Alton 2005 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions Clin Pharmacokinet 44 467 494 1:CAS:528:DC%2BD2MXlvVCrtbs%3D 10.2165/00003088-200544050-00002 15871634
3. L Jeu JW Cheng 2003 Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor Clin Ther 25 2352 2387 1:CAS:528:DC%2BD3sXovFynurY%3D 10.1016/S0149-2918(03)80281-3 14604738
4. EA Nutescu NL Shapiro 2003 Ezetimibe: a selective cholesterol absorption inhibitor Pharmacotherapy 23 1463 1474 1:CAS:528:DC%2BD3sXpt1Kjsb8%3D 10.1592/phco.23.14.1463.31942 14620392
5. M van Heek C Farley DS Compton L Hoos KB Alton EJ Sybertz HR Davis Jr 2000 Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663 Br J Pharmacol 129 1748 1754 10.1038/sj.bjp.0703235 10780982
6. A Ghosal N Hapangama Y Yuan J Achanfuo-Yeboah R Iannucci S Chowdhury K Alton JE Patrick S Zbaida 2004 Identification of human UDP- glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia) Drug Metab Dispos 32 314 320 1:CAS:528:DC%2BD2cXhslOks7Y%3D 10.1124/dmd.32.3.314 14977865
7. F Ezzet G Krishna DB Wexler P Statkevich T Kosoglou VK Batra 2001 A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe Clin Ther 23 871 885 1:CAS:528:DC%2BD3MXltFWktbg%3D 10.1016/S0149-2918(01)80075-8 11440287
8. S Nagar RP Remmel 2006 Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer Oncogene 25 1659 1672 1:CAS:528:DC%2BD28XisFyhtbg%3D 10.1038/sj.onc.1209375 16550166
9. RH Tukey CP Strassburg 2000 Human UDP-glucuronosyltransferases: metabolism, expression, and disease Annu Rev Pharmacol Toxicol 40 581 616 1:CAS:528:DC%2BD3cXjs1yht7k%3D 10.1146/annurev.pharmtox.40.1.581 10836148
10. UGT1A1 allele nomenclature. In: UDP Glucuronosyltransferase Homepage. http://www.pharmacogenomics.pha.ulaval.ca/webdav/site/pharmacogenomics/shared/ Nomenclature/UGT1A/UGT1A1.htm. Accessed 15 April 2009
11. JY Liu K Qu AD Sferruzza RA Bender 2007 Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals Anticancer Drugs 18 693 696 1:CAS:528:DC%2BD2sXmvVWrt78%3D 10.1097/CAD.0b013e32803a46fe 17762398
12. H Minami K Sai M Saeki Y Saito S Ozawa K Suzuki N Kaniwa J Sawada T Hamaguchi N Yamamoto K Shirao Y Yamada H Ohmatsu K Kubota T Yoshida A Ohtsu N Saijo 2007 Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and*28 Pharmacogenet Genomics 17 497 504 1:CAS:528:DC%2BD2sXmtlShs7k%3D 10.1097/FPC.0b013e328014341f 17558305
13. PJ Bosma JR Chowdhury C Bakker S Gantla A de Boer BA Oostra D Lindhout GN Tytgat PL Jansen RP Oude Elferink NR Chowdhury 1995 The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome N Engl J Med 333 1171 1175 1:CAS:528:DyaK2MXpvF2gs7c%3D 10.1056/NEJM199511023331802 7565971
14. Y Maruo C D'Addario A Mori M Iwai H Takahashi H Sato Y Takeuchi 2004 Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome Hum Genet 115 525 526 1:CAS:528:DC%2BD2cXhtVWjt7jF 10.1007/s00439-004-1183-x 15378351
15. L Iyer S Das L Janisch M Wen J Ramírez T Karrison GF Fleming EE Vokes RL Schilsky MJ Ratain 2002 UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity Pharmacogenomics J 2 43 47 1:CAS:528:DC%2BD38Xitl2ju7k%3D 10.1038/sj.tpj.6500072 11990381
16. Y Ando H Saka M Ando T Sawa K Muro H Ueoka A Yokoyama S Saitoh K Shimokata Y Hasegawa 2000 Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 60 6921 6926 1:CAS:528:DC%2BD3MXjsVOjsA%3D%3D 11156391
17. K Yamamoto H Sato Y Fujiyama Y Doida T Bamba 1998 Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene of phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II Biochim Biophys Acta 1406 267 273 1:CAS:528:DyaK1cXjs1ahsLw%3D 9630669
18. W Udomuksorn DJ Elliot BC Lewis PI Mackenzie K Yoovathaworn JO Miners 2007 Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates Pharmacogenet Genom 17 1017 1029 1:CAS:528:DC%2BD2sXhsVWiu7%2FO 10.1097/FPC.0b013e328256b1b6
19. MJ Huang KE Kua HC Teng KS Tang HW Weng CS Huang 2004 Risk factors for severe hyperbilirubinemia in neonates Pediatr Res 56 682 689 1:CAS:528:DC%2BD2cXotlagt7k%3D 10.1203/01.PDR.0000141846.37253.AF 15319464
20. S Oswald E Scheuch I Cascorbi W Siegmund 2006 A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1 J Chromatogr B Analyt Technol Biomed Life Sci 830 143 150 1:CAS:528:DC%2BD2MXhtlCrsLnK 10.1016/j.jchromb.2005. 10.034 16280261
21. S Li G Liu J Jia X Li C Yu 2006 Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of ezetimibe in human plasma J Pharm Biomed Anal 40 987 992 1:CAS:528:DC%2BD28Xhs1Sgtb4%3D 10.1016/j.jpba.2005.07.053 16242881
22. C Guillemette 2003 Pharmacogenomics of human UDP-glucuronosyltransferase enzymes Pharmacogenomics J 3 136 158 1:CAS:528:DC%2BD3sXks1Cnu7w%3D 10.1038/sj.tpj.6500171 12815363
23. K Araki K Fujita Y Ando F Nagashima W Yamamoto H Endo T Miya K Kodama M Narabayashi Y Sasaki 2006 Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer Cancer Sci 97 1255 1259 1:CAS:528:DC%2BD28XhtFemtbbN 10.1111/j.1349-7006. 2006.00321.x 16965601
24. K Sai M Saeki Y Saito S Ozawa N Katori H Jinno R Hasegawa N Kaniwa J Sawada K Komamura K Ueno S Kamakura M Kitakaze Y Kitamura N Kamatani H Minami A Ohtsu K Shirao T Yoshida N Saijo 2004 UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer Clin Pharmacol Ther 75 501 515 1:CAS:528:DC%2BD2cXkslWmtrc%3D 10.1016/j.clpt.2004.01.010 15179405
25. H Cai N Nguyen V Peterkin YS Yang K Hotz D Beaton La Placa S Chen RH Tukey JC Stevens 2010 A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1 dependent glucuronidation Drug Metab Dispos 38 879 886 1:CAS:528:DC%2BC3cXlsFWmsLs%3D 10.1124/dmd.109.030130 20124398
26. T Yamamoto K Ito M Honma T Takada H Suzuki 2007 Cholesterol-lowering effect of ezetimibe in uridine diphosphate glucuronosyltransferase 1A-deficient (Gunn) rats Drug Metab Dispos 35 1455 1458 1:CAS:528:DC%2BD2sXpslKru7w%3D 10.1124/dmd.107.015628 17567728
27. S Oswald S Westrup M Grube HK Kroemer W Weitschies W Siegmund 2006 Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats J Pharmacol Exp Ther 318 1293 1299 1:CAS:528:DC%2BD28XovFygt7Y%3D 10.1124/jpet.106.104018 16772539